See more : Gemina Laboratories Ltd. (GLABF) Income Statement Analysis – Financial Results
Complete financial analysis of Biora Therapeutics, Inc. (BIOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biora Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- All Ring Tech Co., Ltd. (6187.TWO) Income Statement Analysis – Financial Results
- Intellia Therapeutics, Inc. (0JBU.L) Income Statement Analysis – Financial Results
- Hunan Development Group Co.,Ltd (000722.SZ) Income Statement Analysis – Financial Results
- Deceuninck NV (DECB.BR) Income Statement Analysis – Financial Results
- AMCI Acquisition Corp. II (AMCIU) Income Statement Analysis – Financial Results
Biora Therapeutics, Inc. (BIOR)
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 4.00K | 305.00K | 1.25M | 74.31M | 143.99M | 127.97M |
| Cost of Revenue | 0.00 | 907.00K | 1.44M | 93.43M | 100.49M | 92.08M |
| Gross Profit | 4.00K | -602.00K | -190.00K | -19.12M | 43.49M | 35.90M |
| Gross Profit Ratio | 100.00% | -197.38% | -15.24% | -25.73% | 30.21% | 28.05% |
| Research & Development | 29.84M | 24.05M | 45.79M | 47.74M | 63.40M | 48.71M |
| General & Administrative | 0.00 | 0.00 | 68.54M | 75.44M | 61.32M | 51.24M |
| Selling & Marketing | 0.00 | 0.00 | 4.76M | 52.89M | 58.89M | 50.19M |
| SG&A | 37.31M | 38.04M | 73.30M | 128.33M | 120.21M | 101.43M |
| Other Expenses | 0.00 | 2.62M | 5.99M | -25.08M | 0.00 | 0.00 |
| Operating Expenses | 67.15M | 62.09M | 119.08M | 176.07M | 183.61M | 150.14M |
| Cost & Expenses | 67.15M | 62.09M | 119.08M | 269.50M | 284.10M | 242.21M |
| Interest Income | 0.00 | 10.99M | 12.64M | 9.92M | 575.00K | 1.80M |
| Interest Expense | 9.82M | 10.99M | 12.64M | 34.87M | 9.20M | 9.09M |
| Depreciation & Amortization | 555.00K | 907.00K | 1.44M | 1.44M | 4.60M | 4.60M |
| EBITDA | -114.05M | -37.35M | -164.57M | -106.18M | -135.44M | -110.17M |
| EBITDA Ratio | -2,851,350.00% | -19,398.03% | -5,106.66% | -262.66% | -92.51% | -84.93% |
| Operating Income | -67.14M | -61.78M | -117.84M | -195.19M | -140.12M | -114.24M |
| Operating Income Ratio | -1,678,575.00% | -20,256.07% | -9,449.64% | -262.66% | -97.31% | -89.27% |
| Total Other Income/Expenses | -57.28M | 12.53M | -60.80M | -35.00M | -8.62M | -9.62M |
| Income Before Tax | -124.42M | -49.25M | -178.64M | -230.06M | -148.74M | -123.86M |
| Income Before Tax Ratio | -3,110,600.00% | -16,147.54% | -14,325.58% | -309.58% | -103.30% | -96.78% |
| Income Tax Expense | -90.00K | -420.00K | -119.00K | -37.53M | -706.00K | 5.25M |
| Net Income | -124.12M | -48.83M | -178.52M | -192.53M | -148.04M | -129.11M |
| Net Income Ratio | -3,102,875.00% | -16,009.84% | -14,316.04% | -259.08% | -102.81% | -100.88% |
| EPS | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| EPS Diluted | -7.87 | -6.40 | -46.42 | -86.30 | -80.17 | -119.71 |
| Weighted Avg Shares Out | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 15.77M | 7.64M | 3.85M | 2.23M | 1.85M | 1.08M |
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024
Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Call Transcript
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
Biora Therapeutics, Inc. (BIOR) Q4 2022 Earnings Call Transcript
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
10 Top Penny Stocks To Watch With High Short Interest This Week
Source: https://incomestatements.info
Category: Stock Reports